Chuck Royce's HALO Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 74,028 shares of Halozyme Therapeutics, Inc. (HALO) worth $5.43 M, representing 0.05% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Chuck Royce has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 94,310 shares. Largest reduction occurred in Q2 2025, reducing 119,612 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Chuck Royce
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +83,623 | Add 0.00% | 83,622 | $7.94 |
| Q3 2013 | +64,075 | Add 76.62% | 147,697 | $11.04 |
| Q4 2013 | -35,000 | Reduce 23.70% | 112,697 | $14.99 |
| Q1 2014 | -46,622 | Reduce 41.37% | 66,075 | $12.70 |
| Q2 2014 | -64,875 | Reduce 98.18% | 1,200 | $10.00 |
| Q3 2014 | -1,200 | Sold Out | 1,200 | $0.00 |
| Q1 2022 | +32,000 | New Buy | 32,000 | $39.88 |
| Q2 2022 | +64,000 | Add 200.00% | 96,000 | $44.00 |
| Q1 2023 | -51,000 | Reduce 53.12% | 45,000 | $38.19 |
| Q2 2023 | -45,000 | Sold Out | 45,000 | $0.00 |
| Q4 2023 | +139,310 | New Buy | 139,310 | $36.96 |
| Q1 2024 | +52,245 | Add 37.50% | 191,555 | $40.68 |
| Q2 2024 | -14,828 | Reduce 7.74% | 176,727 | $52.36 |
| Q3 2024 | -52,716 | Reduce 29.83% | 124,011 | $57.24 |
| Q4 2024 | +72,988 | Add 58.86% | 196,999 | $47.81 |
| Q1 2025 | +9,642 | Add 4.89% | 206,641 | $63.81 |
| Q2 2025 | -119,612 | Reduce 57.88% | 87,029 | $52.02 |
| Q3 2025 | -13,001 | Reduce 14.94% | 74,028 | $73.34 |
Chuck Royce's Halozyme Therapeutics Investment FAQs
Chuck Royce first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2013, acquiring 83,622 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Halozyme Therapeutics, Inc. (HALO) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2023, adding 139,310 shares worth $5.15 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Chuck Royce's firm, Royce & Associates Lp, owns 74,028 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $5.43 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.05% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce's peak holding in Halozyme Therapeutics, Inc. (HALO) was 206,641 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.